A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
Latest Information Update: 17 Dec 2025
At a glance
- Drugs AZD 6793 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 17 Dec 2025 New trial record